223 related articles for article (PubMed ID: 18491970)
1. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.
Casper C; Krantz EM; Corey L; Kuntz SR; Wang J; Selke S; Hamilton S; Huang ML; Wald A
J Infect Dis; 2008 Jul; 198(1):23-30. PubMed ID: 18491970
[TBL] [Abstract][Full Text] [Related]
2. Valganciclovir for the Suppression of Epstein-Barr Virus Replication.
Yager JE; Magaret AS; Kuntz SR; Selke S; Huang ML; Corey L; Casper C; Wald A
J Infect Dis; 2017 Jul; 216(2):198-202. PubMed ID: 28838145
[TBL] [Abstract][Full Text] [Related]
3. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.
Cattamanchi A; Saracino M; Selke S; Huang ML; Magaret A; Celum C; Corey L; Wald A; Casper C
J Med Virol; 2011 Oct; 83(10):1696-703. PubMed ID: 21837785
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated multicentric Castleman disease.
Oksenhendler E
Curr Opin HIV AIDS; 2009 Jan; 4(1):16-21. PubMed ID: 19343828
[TBL] [Abstract][Full Text] [Related]
6. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda.
Johnston C; Orem J; Okuku F; Kalinaki M; Saracino M; Katongole-Mbidde E; Sande M; Ronald A; McAdam K; Huang ML; Drolette L; Selke S; Wald A; Corey L; Casper C
PLoS One; 2009; 4(1):e4222. PubMed ID: 19156206
[TBL] [Abstract][Full Text] [Related]
7. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
Uldrick TS; Polizzotto MN; Aleman K; O'Mahony D; Wyvill KM; Wang V; Marshall V; Pittaluga S; Steinberg SM; Tosato G; Whitby D; Little RF; Yarchoan R
Blood; 2011 Jun; 117(26):6977-86. PubMed ID: 21487108
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.
Hunt PW; Martin JN; Sinclair E; Epling L; Teague J; Jacobson MA; Tracy RP; Corey L; Deeks SG
J Infect Dis; 2011 May; 203(10):1474-83. PubMed ID: 21502083
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
[TBL] [Abstract][Full Text] [Related]
11. New approaches to the treatment of human herpesvirus 8-associated disease.
Casper C
Rev Med Virol; 2008; 18(5):321-9. PubMed ID: 18615774
[TBL] [Abstract][Full Text] [Related]
12. Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy.
Gantt S; Cattamanchi A; Krantz E; Magaret A; Selke S; Kuntz SR; Huang ML; Corey L; Wald A; Casper C
J Clin Virol; 2014 Jun; 60(2):127-32. PubMed ID: 24698158
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma.
Krown SE; Dittmer DP; Cesarman E
J Infect Dis; 2011 Apr; 203(8):1082-6. PubMed ID: 21450998
[TBL] [Abstract][Full Text] [Related]
14. Oral HHV-8 replication among women in Mombasa, Kenya.
Phipps W; Saracino M; Selke S; Huang ML; Jaoko W; Mandaliya K; Wald A; Casper C; McClelland RS
J Med Virol; 2014 Oct; 86(10):1759-65. PubMed ID: 24692069
[TBL] [Abstract][Full Text] [Related]
15. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ;
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
[TBL] [Abstract][Full Text] [Related]
18. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
19. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.
Bounaadja L; Piret J; Goyette N; Boivin G
J Clin Virol; 2013 Sep; 58(1):279-82. PubMed ID: 23871165
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
